Feb 18 (Reuters) - Chimerix Inc CMRX.O:
CHIMERIX ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR DORDAVIPRONE AS TREATMENT FOR RECURRENT H3 K27M-MUTANT DIFFUSE GLIOMA
CHIMERIX INC - FDA GRANTS PRIORITY REVIEW TO CHIMERIX'S DORDAVIPRONE, PDUFA DATE AUGUST 18, 2025
CHIMERIX INC - NO ADVISORY COMMITTEE MEETING PLANNED FOR CHIMERIX'S DORDAVIPRONE NDA
Source text: ID:nGNX2LbQJt
Further company coverage: CMRX.O